In January 2025, the SCCS accepted the European Commission’s mandate to assess the safety of Cannabidiol. The Scientific Committee on Consumer Safety has just published its preliminary Opinion.
Background
Cannabidiol (CBD) (CAS No.3956-29-1, EC No.689-176-3) is one of the approximately hundred naturally occurring cannabinoids found in Cannabis plants and may account for up to 40% of the plant’s extract. It is included in the CosIng with the reported functions of “skin conditioning”, “skin protecting”, “antioxidant”, “anti-sebum”, etc.
Considering the very limited available information regarding the safety of CBD in cosmetic products, and to enable the SCCS to perform a safety assessment, a call for data was launched from 1 June 2023 to 30 September 2024.
For an exhaustive background information, see the article
• Thimerosal, Phenylmercuric salts, Cannabidiol: requests for SCCS Opinion, CosmeticOBS, 3 February 2025
The SCCS Opinion
(1) Taking under consideration the information/data submitted via the respective call for data, the SCCS is requested:
(a) to assess the maximum concentration of Cannabidiol that is considered safe when used in cosmetic products;
In view of all the available data, the SCCS considers CBD safe when used at concentrations up to 0.19% in dermal cosmetic products and oral cosmetic products – whether used alone or together.
(b) to identify the maximum safe level of Delta-9-tetrahydrocannabinol (THC) present as a contaminant …
